NCRP for Cardiovascular and Metabolic Disease, South African Medical Research Council and University of Cape Town, South Africa.
Diab Vasc Dis Res. 2013 Mar;10(2):143-51. doi: 10.1177/1479164112451588. Epub 2012 Jul 11.
We assessed the associations of fibrinogen levels with cardiovascular disease (CVD) risks in people with and without diabetes, and quantified the value of adding fibrinogen to the established predictive algorithms for CVD.
We used Cox models to analyse data from prospective cohorts totalling 33,091 adults (1006 with diabetes) who took part in British and Scottish general population-based health surveys. Discrimination was assessed through c-statistic.
During a median follow-up of 116 months, 351 deaths (119 CVD) were recorded in participants with diabetes and 4157 deaths (1167 CVD) in those without. After adjustment for age and sex, fibrinogen (per standard deviation log(e)) was positively associated with a 34% (26-42%) higher risk of cardiovascular disease and 30% (26-35%) greater risk all-cause mortality. These associations were log-linear, similar in people with and without diabetes (p-value for interaction ≥0.21), robust to the adjustment of additional major CVD risk factors. Adding fibrinogen to a model containing conventional CVD risk factors resulted in only modest improvement in risk prediction.
The associations of fibrinogen with CVD and all-cause mortality are broadly similar in people with and without diabetes status. Improvement in predictive accuracy after adding fibrinogen to established risk factors is not clinically important.
我们评估了纤维蛋白原水平与糖尿病患者和非糖尿病患者心血管疾病(CVD)风险的相关性,并量化了将纤维蛋白原加入 CVD 既定预测算法的价值。
我们使用 Cox 模型分析了来自英国和苏格兰基于人群的健康调查的 33091 名成年人(1006 名患有糖尿病)的前瞻性队列数据。通过 c 统计量评估判别能力。
在中位数为 116 个月的随访期间,糖尿病患者中有 351 人(119 例 CVD)死亡,非糖尿病患者中有 4157 人(1167 例 CVD)死亡。在调整年龄和性别后,纤维蛋白原(每标准偏差对数(e))与心血管疾病风险增加 34%(26-42%)和全因死亡率增加 30%(26-35%)相关。这些关联呈对数线性,在有糖尿病和无糖尿病的人群中相似(交互作用 p 值≥0.21),并且在调整其他主要 CVD 风险因素后仍然稳健。将纤维蛋白原加入包含传统 CVD 风险因素的模型中仅略微改善了风险预测。
纤维蛋白原与 CVD 和全因死亡率的相关性在有糖尿病和无糖尿病状态的人群中大致相似。将纤维蛋白原加入既定风险因素后,预测准确性的提高在临床上并不重要。